Cannabinoid Research Studies
Procana is accepting applications to further its own studies in these areas.
What is Antibiotic Resistance?
Antibiotic resistance occurs when an antibiotic has lost its ability to effectively control or kill bacterial growth; in other words, the bacteria are "resistant" and continue to multiply in the presence of therapeutic levels of an antibiotic
Procana Medical Studies [Apply]
Procana is accepting applicants to participate in medical studies of controlled dosage CBD for the treatment of Antibiotic Resistance. “CBD” Cannabidiol subset studies will be derived from either Cannabis “Marijuana” or Industrial Hemp. Other medical studies may include ratios of “THC” Tetrahydrocannabinol derived from Cannabis, also known as Marijuana to study the treatment for Antibiotic Resistance.
Procana does not warrant, nor does it have approval from the FDA to claim, diagnose or treat any illness or disease with its products containing Hemp, Cannabis or Marijuana with THC or CBD for the treatment of Antibiotic Resistance.
To participate in these ongoing studies, please click here.
Most of the PubMed material consists of abstracts on preclinical research involving single cannabinoid molecules, test tubes, petri dishes, animal experiments, and in some cases human cell-line studies. Although all mammals have cell receptors that respond pharmacologically to cannabinoid compounds, data from animal experiments and other preclinical research is not always applicable to humans.
This data may include articles, surveys, studies or opinions related to THC and CBD from either Marijuana, Cannabis or Hemp in the use of Antibiotic Resistance. This information is for research purposes only, and does not include the use of Procana products.